Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRS001
MIFTS: 52

Serous Cystadenocarcinoma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Serous Cystadenocarcinoma

About this section

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 15
Cystadenocarcinoma, Serous 44 71
Serous Adenocarcinoma 12 17
Cystadenocarcinoma Serous 54
Serous Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3114
MeSH 44 D018284
NCIt 50 C3778
SNOMED-CT 67 90725004
UMLS 71 C0206701
Sources

Summaries for Serous Cystadenocarcinoma

About this section
Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to endometrial serous adenocarcinoma and papillary serous adenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Everolimus and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and lymph node, and related phenotypes are Increased cell death in HCT116 cells and cardiovascular system

Wikipedia : 74 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Sources

Related Diseases for Serous Cystadenocarcinoma

About this section

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 endometrial serous adenocarcinoma 32.5 TP53 PPP2R1A PIK3CA PGR FBXW7 ERBB2
2 papillary serous adenocarcinoma 32.4 TP53 PGR HRAS
3 fallopian tube carcinoma 32.0 VEGFA TP53 PGR MMP2 ERBB2
4 ovarian serous cystadenocarcinoma 31.3 ZNF217 YAP1 VEGFA TP53 PPP2R1A PIK3CA
5 ovarian cystadenocarcinoma 31.3 ZNF217 TP53 PIK3CA MUC16 HRAS ERBB2
6 adenocarcinoma 30.9 VEGFA TP53 PIK3CA MMP2 HRAS ERBB2
7 cervical adenocarcinoma 30.9 TP53 ERBB2 CDKN1A AKT1
8 papillary adenocarcinoma 30.9 TP53 PGR MUC16 ERBB2
9 endometrioid ovary carcinoma 30.8 TP53 PPP2R1A PIK3CA
10 clear cell adenocarcinoma 30.8 TP53 PIK3CA MUC16
11 adenofibroma 30.8 TP53 MUC16 BRAF
12 ovarian carcinosarcoma 30.6 TP53 PIK3CA ERBB2
13 papilloma 30.5 VEGFA TP53 ERBB2 CDKN1A AKT1
14 endometrial adenocarcinoma 30.5 VEGFA TP53 PGR ESR2 ERBB2 AKT1
15 endometrial hyperplasia 30.5 VEGFA TP53 PGR ESR2
16 squamous cell papilloma 30.5 TP53 HRAS
17 ovarian clear cell carcinoma 30.5 ZNF217 VEGFA TP53 PPP2R1A PIK3CA MUC16
18 uterine corpus endometrial carcinoma 30.5 TP53 PPP2R1A PIK3CA HRAS FBXW7
19 adenoma 30.5 TP53 PIK3CA BRAF AKT1
20 mature teratoma 30.4 TP53 NANOG ERBB2 BRAF
21 carcinosarcoma 30.4 TP53 PPP2R1A PIK3CA PGR HRAS FBXW7
22 adenosquamous carcinoma 30.4 TP53 PIK3CA PGR
23 nonseminomatous germ cell tumor 30.4 ERBB2 BRAF
24 tuberous sclerosis 1 30.4 TP53 PIK3CA AKT1
25 endocervical adenocarcinoma 30.4 TP53 PIK3CA PGR ERBB2 CDKN1A
26 in situ carcinoma 30.4 TP53 PIK3CA PGR HRAS ERBB2 AKT1
27 tuberous sclerosis 30.4 VEGFA TP53 PIK3CA AKT1
28 clear cell adenofibroma 30.4 PPP2R1A PIK3CA
29 adenomyosis 30.3 VEGFA TP53 PGR MMP2 ESR2
30 ovarian seromucinous carcinoma 30.3 TP53 PGR
31 apocrine adenocarcinoma 30.3 TP53 PGR ERBB2
32 bilateral breast cancer 30.3 PIK3CA PGR ERBB2
33 primary peritoneal carcinoma 30.3 VEGFA TP53 PGR MUC16 ERBB2
34 ovarian clear cell adenocarcinoma 30.3 VEGFA TP53 PIK3CA ESR2
35 wilms tumor 1 30.3 TP53 PGR FBXW7 ERBB2 BRAF BIRC5
36 transitional cell carcinoma 30.3 TP53 HRAS ERBB2 CDKN1A BRAF BIRC5
37 endocervical carcinoma 30.2 TP53 PIK3CA PGR ERBB2
38 breast ductal carcinoma 30.2 VEGFA TP53 PGR ESR2 ERBB2 CDKN1A
39 cervical squamous cell carcinoma 30.2 VEGFA TP53 PIK3CA MMP2 AKT1
40 rectum adenocarcinoma 30.2 TP53 PIK3CA HRAS FBXW7 ERBB2
41 cystadenocarcinoma 30.2 ZNF217 YAP1 VEGFA TP53 PPP2R1A PIK3CA
42 testicular germ cell tumor 30.2 HRAS CDKN1A BRAF
43 pancreatic ductal carcinoma 30.2 VEGFA TP53 MUC16 ERBB2
44 high grade glioma 30.2 VEGFA TP53 PIK3CA BIRC5
45 exanthem 30.1 VEGFA HRAS ERBB2 AKT1
46 pilocytic astrocytoma 30.1 TP53 PIK3CA NRAS HRAS BRAF AKT1
47 pelvic organ prolapse 30.1 TP53 PGR MMP2 ESR2
48 endometriosis 30.1 VEGFA PGR MUC16 MMP2 ESR2
49 malignant astrocytoma 30.1 VEGFA TP53 ERBB2 BRAF AKT1
50 mucinous adenocarcinoma 30.1 VEGFA TP53 PGR MUC16 ERBB2

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma
Sources

Symptoms & Phenotypes for Serous Cystadenocarcinoma

About this section

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in HCT116 cells GR00103-A-0 8.8 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.48 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
2 cellular MP:0005384 10.47 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
3 homeostasis/metabolism MP:0005376 10.47 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
4 endocrine/exocrine gland MP:0005379 10.44 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
5 growth/size/body region MP:0005378 10.43 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
6 behavior/neurological MP:0005386 10.42 AKT1 BRAF CDKN1A ERBB2 ESR2 HRAS
7 embryo MP:0005380 10.42 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
8 mortality/aging MP:0010768 10.41 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
9 immune system MP:0005387 10.37 AKT1 B2M BIRC5 BRAF CDKN1A ESR2
10 integument MP:0010771 10.36 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
11 hematopoietic system MP:0005397 10.33 AKT1 B2M BIRC5 BRAF CDKN1A ESR2
12 digestive/alimentary MP:0005381 10.32 B2M BRAF CDKN1A ERBB2 ESR2 FBXW7
13 neoplasm MP:0002006 10.31 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
14 craniofacial MP:0005382 10.24 BRAF CDKN1A ERBB2 FBXW7 HRAS MMP2
15 muscle MP:0005369 10.21 AKT1 BRAF CDKN1A ERBB2 ESR2 HRAS
16 liver/biliary system MP:0005370 10.18 AKT1 B2M BRAF CDKN1A ESR2 FBXW7
17 nervous system MP:0003631 10.18 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
18 limbs/digits/tail MP:0005371 10.1 BRAF CDKN1A ERBB2 ESR2 NRAS PGR
19 normal MP:0002873 10.07 AKT1 BIRC5 BRAF ERBB2 ESR2 FBXW7
20 no phenotypic analysis MP:0003012 9.97 CDKN1A ESR2 HRAS NANOG NRAS PGR
21 reproductive system MP:0005389 9.85 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
22 respiratory system MP:0005388 9.7 AKT1 BRAF CDKN1A ERBB2 ESR2 FBXW7
23 skeleton MP:0005390 9.4 AKT1 BRAF CDKN1A ERBB2 ESR2 HRAS
Sources

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
2
Pembrolizumab Approved Phase 3 1374853-91-4
3
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
4
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
7
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
8
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
9
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
10
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
11
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
12
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
13
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
14
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
15
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
16
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
17
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
18
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
19
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
20
Oregovomab Investigational Phase 3 213327-37-8
21 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
22 Carotenoids Phase 3
23 Tubulin Modulators Phase 3
24 Antineoplastic Agents, Immunological Phase 3
25 Estrogens Phase 2, Phase 3
26 Antimitotic Agents Phase 3
27 Aromatase Inhibitors Phase 2, Phase 3
28 Estrogen Antagonists Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3
30 Hormones Phase 2, Phase 3
31 Estrogen Receptor Antagonists Phase 2, Phase 3
32 Anti-Infective Agents Phase 3
33 Antimetabolites Phase 3
34 Antiviral Agents Phase 3
35 topoisomerase I inhibitors Phase 3
36 Hypoglycemic Agents Phase 2, Phase 3
37 Antineoplastic Agents, Hormonal Phase 2, Phase 3
38 taxane Phase 3
39 Protective Agents Phase 2, Phase 3
40 Antioxidants Phase 2, Phase 3
41 Estrogen Receptor Modulators Phase 2, Phase 3
42 Citrate Phase 2, Phase 3
43 Albumin-Bound Paclitaxel Phase 2, Phase 3
44 Etoposide phosphate Phase 2, Phase 3
45 Immunoglobulin G Phase 2, Phase 3
46 Antibiotics, Antitubercular Phase 2, Phase 3
47 Immunoglobulins Phase 2, Phase 3
48 Mitogens Phase 2, Phase 3
49 Anti-Bacterial Agents Phase 2, Phase 3
50 Antibodies, Monoclonal Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
3 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
4 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
6 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
7 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
8 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
9 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
10 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
11 A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Recruiting NCT04498117 Phase 3 Paclitaxel;Carboplatin
12 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
13 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
14 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
15 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan;Trametinib Dimethyl Sulfoxide
17 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
18 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
19 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
20 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum Active, not recruiting NCT01849874 Phase 3 MEK162, MEK inhibitor; oral;Physician's choice chemotherapy
21 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Not yet recruiting NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
22 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
23 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
24 A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum Completed NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate
25 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
26 Phase II Randomized Trial of ABT-888 in Combination With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal, Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, or Triple-Negative Breast Cancer Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
27 A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
28 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
29 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxaneâ„¢) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
30 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
31 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
32 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
33 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
34 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
35 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
36 A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
37 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
38 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
39 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
40 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
41 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
42 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
43 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
44 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
45 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
46 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
47 Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum Completed NCT01583322 Phase 2 vargatef;placebo
48 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
49 Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer Recruiting NCT03462342 Phase 2 Olaparib Pill
50 A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma Recruiting NCT04590248 Phase 2 Adavosertib

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Sources

Genetic Tests for Serous Cystadenocarcinoma

About this section
Sources

Anatomical Context for Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

40
Ovary, Pancreas, Lymph Node, Cervix, Uterus, Endothelial, Spleen
Sources

Publications for Serous Cystadenocarcinoma

About this section

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 1151)
# Title Authors PMID Year
1
Dipeptidyl peptidase IV in tumor progression. 54 61
16054016 2005
2
Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. 54 61
12019149 2002
3
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential. 54 61
11063654 2000
4
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. 54 61
9852392 1999
5
Solitary splenic metastasis of an adenocarcinoma of the ovaries. 54 61
8938479 1996
6
Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. 54 61
8669868 1995
7
The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125. 61 54
8494699 1993
8
Serum and tissue measurements of CA72-4 in ovarian cancer patients. 54 61
8381375 1993
9
[An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. 61 54
1506732 1992
10
NFAT Overexpression Correlates with CA72-4 and Poor Prognosis of Ovarian Clear-Cell Carcinoma Subtype. 61
33125687 2021
11
Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma. 61
33049689 2021
12
Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation. 61
33186060 2021
13
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma. 61
33452985 2021
14
Oncogenes in high grade serous adenocarcinoma of the ovary. 61
33488950 2020
15
Ovarian Carcinosarcoma with Retroperitoneal Para-Aortic Lymph Node Dissemination Followed by an Unusual Postoperative Complication: A Case Report with a Brief Literature Review. 61
33322259 2020
16
Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases. 61
33300090 2020
17
Identification of key factors associated with early- and late-onset ovarian serous cystadenocarcinoma. 61
32885674 2020
18
Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer. 61
33231569 2020
19
Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers. 61
33247676 2020
20
Primary retroperitoneal serous adenocarcinoma: A case report of rare malignancy with literature review. 61
33402586 2020
21
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2020
22
MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells. 61
33313239 2020
23
Cardamonin inhibits cell proliferation by caspase-mediated cleavage of Raptor. 61
33043385 2020
24
A 47-Year-Old Woman With Pulmonary Nodules and Facial Hemispasms. 61
33036119 2020
25
SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors. 61
32663767 2020
26
MONET: Multi-omic module discovery by omic selection. 61
32931516 2020
27
FBXW7γ is a tumor-suppressive and prognosis-related FBXW7 transcript isoform in ovarian serous cystadenocarcinoma. 61
32915667 2020
28
Appendageal tumors and tumor-like lesions of the testis and paratestis: a 32-year experience at a single institution. 61
32619438 2020
29
The Study of the Expression of CGB1 and CGB2 in Human Cancer Tissues. 61
32957442 2020
30
Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer. 61
32880385 2020
31
Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery. 61
32772926 2020
32
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. 61
32382997 2020
33
Outcomes of surgical resection for pulmonary metastasis from ovarian cancer. 61
32703262 2020
34
Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. 61
32565967 2020
35
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. 61
32356124 2020
36
Sunitinib as Successful Maintenance Therapy for Recurrent Pancreatic Serous Cystadenocarcinoma. 61
32541193 2020
37
Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets. 61
32533167 2020
38
Ancestry-specific predisposing germline variants in cancer. 61
32471518 2020
39
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. 61
32227579 2020
40
Serous Microcystic Cystadenocarcinoma of the Pancreas with Synchronous Liver Metastases: Clinical Characteristics and Management. 61
32431986 2020
41
A common variant rs2272804 in the 5'UTR of RIBC2 inhibits downstream gene expression by creating an upstream open reading frame. 61
32329860 2020
42
Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. 61
32105524 2020
43
Synchronous Cervical Adenocarcinoma and Ovarian Serous Adenocarcinoma-A Case Report and Literature Review. 61
32235322 2020
44
The androgen receptor expression and association with patient's survival in different cancers. 61
31759122 2020
45
Pan-cancer diagnostic consensus through searching archival histopathology images using artificial intelligence. 61
33594249 2020
46
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. 61
32190072 2020
47
Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells. 61
31723239 2020
48
Fallopian tube serous adenocarcinoma with dizziness as the initial symptom: a case report. 61
31500488 2020
49
ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy. 61
31478407 2020
50
The association between expression of p53 and aggressiveness of serous adenocarcinoma of the uterine cervix. 61
32765617 2020
Sources

Variations for Serous Cystadenocarcinoma

About this section
Sources

Expression for Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Serous Cystadenocarcinoma.
Sources

Pathways for Serous Cystadenocarcinoma

About this section

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.31 YAP1 VEGFA TP53 PPP2R1A PIK3CA PGR
2
Innate Immune System 65
Show member pathways
 14.07 VEGFA TP53 PPP2R1A PIK3CA NRAS NANOG
3
ERK Signaling 63
Show member pathways
 13.95 VEGFA TP53 PPP2R1A NRAS HRAS ESR2
4
Gene Expression 65
Show member pathways
 13.93 YAP1 VEGFA TP53 PPP2R1A PGR ESR2
5
HIV Life Cycle 65
Show member pathways
 13.86 PPP2R1A PIK3CA NRAS MUC16 HRAS FBXW7
6
GPCR Pathway 63
Show member pathways
 13.83 VEGFA TP53 PPP2R1A NRAS MMP2 HRAS
7
TGF-Beta Pathway 63
Show member pathways
 13.69 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
8
Developmental Biology 65
Show member pathways
 13.65 VEGFA PPP2R1A PIK3CA NRAS NANOG MMP2
9
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.6 TP53 PPP2R1A PIK3CA NRAS HRAS FBXW7
10
Akt Signaling 63
Show member pathways
 13.54 YAP1 TP53 PPP2R1A NRAS HRAS ERBB2
11
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.43 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
12
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.42 YAP1 VEGFA PPP2R1A NRAS NANOG HRAS
13
TNFR1 Pathway 63
Show member pathways
 13.23 VEGFA TP53 PIK3CA NRAS HRAS CDKN1A
14
GAB1 signalosome 65
Show member pathways
 13.22 TP53 PPP2R1A PIK3CA ERBB2 CDKN1A AKT1
15
Cytokine Signaling in Immune system 65
Show member pathways
 13.21 VEGFA TP53 PPP2R1A PIK3CA NRAS NANOG
16
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.2 TP53 PPP2R1A PIK3CA NRAS HRAS CDKN1A
17
PI3K-Akt signaling pathway 36
Show member pathways
 13.12 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
18
fMLP Pathway 63
Show member pathways
 13.11 VEGFA TP53 NRAS HRAS BRAF AKT1
19
Human cytomegalovirus infection 36
Show member pathways
 13.1 VEGFA TP53 PIK3CA NRAS HRAS CDKN1A
20
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.06 VEGFA PIK3CA NRAS HRAS ERBB2 BRAF
21
Focal Adhesion 36 1
Show member pathways
 13.06 VEGFA PIK3CA NRAS HRAS ERBB2 BRAF
22
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13 PIK3CA NRAS HRAS ERBB2 BRAF AKT1
23
Endometrial cancer 36
Show member pathways
 12.96 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
24
Development Angiotensin activation of ERK 23
Show member pathways
 12.95 PIK3CA NRAS HRAS BRAF AKT1
25
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.93 PIK3CA HRAS CDKN1A BRAF BIRC5 AKT1
26
MAPK signaling pathway 36 1
12.93 VEGFA TP53 NRAS HRAS ERBB2 BRAF
27
Measles 36
Show member pathways
 12.92 TP53 PIK3CA CDKN1A B2M AKT1
28
Beta-Adrenergic Signaling 63
Show member pathways
 12.91 PPP2R1A NRAS HRAS BRAF AKT1
29
Ras signaling pathway 36
Show member pathways
 12.89 VEGFA PIK3CA NRAS HRAS BRAF AKT1
30
Circadian entrainment 36
Show member pathways
 12.88 PPP2R1A PIK3CA NRAS HRAS AKT1
31
Development HGF signaling pathway 23
Show member pathways
 12.88 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
32
Apoptosis Modulation and Signaling 1
Show member pathways
 12.87 TP53 PIK3CA NRAS HRAS CDKN1A BIRC5
33
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.87 TP53 PPP2R1A PIK3CA NRAS HRAS ERBB2
34
4-1BB Pathway 63
Show member pathways
 12.83 TP53 PPP2R1A NRAS HRAS BRAF AKT1
35
Relaxin signaling pathway 36
Show member pathways
 12.81 VEGFA PIK3CA PGR NRAS MMP2 HRAS
36
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.77 PIK3CA NRAS MMP2 HRAS AKT1
37
Gastric cancer 36
Show member pathways
 12.77 TP53 PIK3CA PGR NRAS HRAS ESR2
38
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.72 VEGFA PIK3CA NRAS HRAS AKT1
39
Negative regulation of FGFR1 signaling 65
Show member pathways
 12.71 PPP2R1A PIK3CA NRAS HRAS BRAF
40
MicroRNAs in cancer 36
12.7 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
41
ErbB signaling pathway 36 1
Show member pathways
 12.7 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
42
VEGF Signaling 66
Show member pathways
 12.67 VEGFA TP53 PIK3CA NRAS HRAS AKT1
43
Glioma 36
Show member pathways
 12.67 TP53 PIK3CA NRAS MMP2 HRAS ESR2
44
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.66 TP53 PPP2R1A PIK3CA HRAS CDKN1A AKT1
45
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.66 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
46
Prolactin Signaling Pathway 1 36
Show member pathways
 12.65 PIK3CA NRAS HRAS ESR2 ERBB2 AKT1
47
Apoptosis Pathway 70
Show member pathways
 12.62 TP53 PIK3CA NRAS HRAS ERBB2 AKT1
48
Development IGF-1 receptor signaling 23
Show member pathways
 12.57 TP53 PIK3CA HRAS CDKN1A BIRC5 AKT1
49
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.56 PIK3CA NRAS HRAS BRAF AKT1
50
VEGF Pathway (Qiagen) 63
Show member pathways
 12.55 VEGFA PIK3CA NRAS HRAS AKT1
Sources

GO Terms for Serous Cystadenocarcinoma

About this section

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 ZNF217 YAP1 TP53 PGR NANOG HRAS
2 cytosol GO:0005829 9.97 YAP1 TP53 PPP2R1A PIK3CA PGR HRAS
3 nucleus GO:0005634 9.83 ZNF217 YAP1 TP53 PPP2R1A PGR NANOG
4 mitochondrion GO:0005739 9.28 ZNF217 TP53 PPP2R1A PGR MMP2 FBXW7

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.13 ZNF217 YAP1 VEGFA TP53 NANOG ESR2
2 cellular response to DNA damage stimulus GO:0006974 10.04 YAP1 TP53 FBXW7 CDKN1A AKT1
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.03 YAP1 VEGFA TP53 PGR NANOG HRAS
4 positive regulation of cell proliferation GO:0008284 9.99 YAP1 VEGFA HRAS ERBB2 BIRC5 AKT1
5 negative regulation of apoptotic process GO:0043066 9.95 VEGFA TP53 CDKN1A BRAF BIRC5 AKT1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 VEGFA HRAS FBXW7 BRAF
7 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA HRAS ERBB2 AKT1
8 transcription initiation from RNA polymerase II promoter GO:0006367 9.87 YAP1 PGR ESR2 CDKN1A
9 negative regulation of neuron apoptotic process GO:0043524 9.84 PIK3CA HRAS BRAF BIRC5
10 positive regulation of endothelial cell proliferation GO:0001938 9.81 VEGFA NRAS AKT1
11 negative regulation of cell growth GO:0030308 9.8 TP53 PPP2R1A ESR2 CDKN1A
12 positive regulation of gene expression GO:0010628 9.8 YAP1 VEGFA TP53 HRAS ERBB2 BRAF
13 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.79 VEGFA BIRC5 AKT1
14 vasculogenesis GO:0001570 9.77 YAP1 VEGFA FBXW7
15 somatic stem cell population maintenance GO:0035019 9.77 YAP1 NANOG BRAF
16 positive regulation of MAP kinase activity GO:0043406 9.76 VEGFA HRAS ERBB2
17 epidermal growth factor receptor signaling pathway GO:0007173 9.73 PIK3CA BRAF AKT1
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 VEGFA PIK3CA BRAF AKT1
19 phosphatidylinositol 3-kinase signaling GO:0014065 9.7 PIK3CA ERBB2 AKT1
20 Ras protein signal transduction GO:0007265 9.67 TP53 NRAS HRAS CDKN1A
21 anoikis GO:0043276 9.64 PIK3CA AKT1
22 intracellular steroid hormone receptor signaling pathway GO:0030518 9.64 PGR ESR2
23 regulation of cell cycle G1/S phase transition GO:1902806 9.63 FBXW7 CDKN1A
24 intrinsic apoptotic signaling pathway GO:0097193 9.63 TP53 HRAS CDKN1A
25 progesterone receptor signaling pathway GO:0050847 9.62 YAP1 PGR
26 positive regulation of epithelial cell proliferation GO:0050679 9.62 YAP1 VEGFA HRAS ERBB2
27 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.58 VEGFA TP53
28 negative regulation of gene expression GO:0010629 9.56 YAP1 VEGFA TP53 PGR HRAS FBXW7
29 signal transduction by p53 class mediator GO:0072331 9.55 TP53 CDKN1A
30 cellular response to gamma radiation GO:0071480 9.46 YAP1 TP53 HRAS CDKN1A
31 cytokine-mediated signaling pathway GO:0019221 9.23 VEGFA TP53 PIK3CA NANOG MMP2 CDKN1A

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 ZNF217 YAP1 VEGFA TP53 PPP2R1A PIK3CA
2 transcription regulatory region sequence-specific DNA binding GO:0000976 9.56 ZNF217 YAP1 TP53 NANOG
3 enzyme binding GO:0019899 9.55 TP53 PGR ESR2 BIRC5 AKT1
4 identical protein binding GO:0042802 9.32 VEGFA TP53 PGR FBXW7 ESR2 ERBB2
Sources

Sources for Serous Cystadenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....